MiNK Therapeutics (INKT)

• Market cap: $64.5M
• 1 day: -0.9%
• 5 days: -7.94%
• 1 month: -4.29%
• 3 months: 88.51%
• 6 months: 67.49%
• Year to date: 41.29%
• 1 year: 89.76%
• 5 years: -88.11%
• 10 years: -88.11%
• Sector: Healthcare
• Industry: Biotechnology

About: MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Employees: 23

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

12% more funds holding

Funds holding: 17 [Q1] → 19 (+2) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

0.03% less ownership

Funds ownership: 1.59% [Q1] → 1.55% (-0.03%) [Q2]

15% less capital invested

Capital invested by funds: $544K [Q1] → $460K (-$84.2K) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $35
• Avg. target: $35
• High target: $35

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Emily Bodnar

$35

Buy Upgraded

15 Aug 2025